Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14932546 | 0.85 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2GAAHTTL3MBTL1 | |
| Hydrochloric Acid SCHEMBL783933 | 0.84 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2GAAHTTL3MBTL1 | |
| SCHEMBL12871592 | 0.82 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2GAAHTTL3MBTL1 | |
| SCHEMBL29721809 | 0.80 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2GAAHTTL3MBTL1 | |
| SCHEMBL14920829 | 0.79 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2GAAHTTL3MBTL1 | |
| SCHEMBL20181749 | 0.79 | LMNA (0.35) | SMN1; SMN2HTTL3MBTL1PLAUKMT2A | |
| SCHEMBL14920954 | 0.77 | SMN1; SMN2 (0.49) | ALDH1A1SMN1; SMN2GAAL3MBTL1POLB | |
| SCHEMBL14920461 | 0.75 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2GAAHTTL3MBTL1 | |
| SCHEMBL18811741 | 0.75 | RXRA (0.33) | — | |
| SCHEMBL20457093 | 0.75 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2GAAHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008339-B2 | Substituted pyrazole compounds containing pyrimidine and preparation method and use thereof | SHENYANG SINOCHEM AGROCHEMICALS R&D CO., LTD. (CN) | 2021-05-18 | — | — | US | disclosed |
| US-10301296-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | NOVARTIS AG (CH) | 2019-05-28 | — | — | US | disclosed |
| US-20180141961-A1 | Substituted Pyrazole Compounds Containing Pyrimidine and Preparation Method and Use Thereof | SHENYANG SINOCHEM AGROCHEMICALS R&D CO., LTD. (CN) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141961-A1 | Substituted Pyrazole Compounds Containing Pyrimidine and Preparation Method and Use Thereof | APRT, GART, PNP | ALDH1A1 1748/4885SMN1; SMN2 3208/4885GAA 1314/4885 |
| US-10301296-B2 | Heterocyclic derivatives and their use in the treatment of neurological disorders | BACE2, BACE1, PSEN2 | ALDH1A1 500/4885SMN1; SMN2 66/4885GAA 8/4885 |
| US-11008339-B2 | Substituted pyrazole compounds containing pyrimidine and preparation method and use thereof | APRT, GART, PNP | ALDH1A1 1748/4885SMN1; SMN2 3208/4885GAA 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.